Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Nasu, Akihiro ^a   Marusawa, Hiroyuki ^a   Ueda, Yoshihide ^a   Nishijima, Norihiro ^a   Takahashi, Ken ^a   Osaki, Yukio ^b   Yamashita, Yukitaka ^c   Inokuma, Tetsuro ^d   Tamada, Takashi ^e   Fujiwara, Takeshi ^a   Sato, Fumiaki ^a   Shimizu, Kazuharu ^a   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

^c JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

^d KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^e TAKATSUKI RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BI 201335; BOCEPREVIR; DANOPREVIR; FILIBUVIR; MERICITABINE; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; VANIPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; COMPLEMENTARY DNA; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; AGED; ANALYZER; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; SEQUENCE ANALYSIS; SPECIES DIFFERENCE; ULTRA DEEP SEQUENCING; VIRUS GENOME; VIRUS MUTATION; CHEMISTRY; DRUG COMBINATION; DRUG EFFECT; GENETICS; HIGH THROUGHPUT SEQUENCING; METHODOLOGY; MIDDLE AGED; MUTATION; MUTATION RATE; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

AGED; ANTIVIRAL AGENTS; BASE SEQUENCE; DNA, COMPLEMENTARY; DRUG THERAPY, COMBINATION; FEMALE; GENETIC HETEROGENEITY; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 80053081987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024907     Document Type: Article

References (42)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362.
2. Grakoui A, Wychowski C, Lin C, Feinstone S, Rice C, (1993) Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67: 1385-1395.
3. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K, (1991) Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 88: 5547-5551.
4. Steinhauer DA, Domingo E, Holland JJ, (1992) Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 122: 281-288.
5. Neumann A, Lam N, Dahari H, Gretch D, Wiley T, et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103-107.
6. Ogata N, Alter H, Miller R, Purcell R, (1991) Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 88: 3392-3396.
7. Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, et al. (1992) Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 190: 894-899.
8. Martell M, Esteban J, Quer J, Genescà J, Weiner A, et al. (1992) Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66: 3225-3229.
9. Pawlotsky J, (2006) Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol 299: 261-284.
10. Argentini C, Genovese D, Dettori S, Rapicetta M, (2009) HCV genetic variability: from quasispecies evolution to genotype classification. Future Microbiol 4: 359-373.
11. Margulies M, Egholm M, Altman W, Attiya S, Bader J, et al. (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437: 376-380.
12. Mardis E, (2009) New strategies and emerging technologies for massively parallel sequencing: applications in medical research. Genome Med 1: 40.
13. Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, et al. (2010) Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 5: e11345.
14. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, et al. (2009) Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 199: 693-701.
15. Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, et al. (2009) Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 4: e5683.
16. Wang GP, Sherrill-Mix SA, Chang KM, Quince C, Bushman FD, (2010) Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol 84: 6218-6228.
17. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, et al. (2009) Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 199: 1275-1285.
18. Marusawa H, Hijikata M, Chiba T, Shimotohno K, (1999) Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol 73: 4713-4720.
19. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Ohkoshi S, et al. (1991) Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 175: 220-228.
20. Sarrazin C, Zeuzem S, (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447-462.
21. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, et al. (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 48: 1769-1778.
22. Lauring AS, Andino R, (2010) Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 6: e1001005.
23. Fishman SL, Branch AD, (2009) The quasispecies nature and biological implications of the hepatitis C virus. Infect Genet Evol 9: 1158-1167.
24. Xu Z, Fan X, Xu Y, Di Bisceglie AM, (2008) Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a. J Virol 82: 9417-9424.
25. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, et al. (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77-81.
26. Pascu M, Martus P, Höhne M, Wiedenmann B, Hopf U, et al. (2004) Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 53: 1345-1351.
27. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, et al. (2007) Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46: 403-410.
28. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, et al. (2002) Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 99: 3081-3086.
29. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
30. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
31. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
32. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
33. Thompson AJ, McHutchison JG, (2009) Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 16: 377-387.
34. López-Labrador FX, Moya A, Gonzàlez-Candelas F, (2008) Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 13: 481-494.
35. Colson P, Brouk N, Lembo F, Castellani P, Tamalet C, et al. (2008) Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patient. Hepatology 47: 766-767.
36. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, et al. (2008) Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 198: 800-807.
37. Lu L, Mo H, Pilot-Matias TJ, Molla A, (2007) Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759. Antimicrob Agents Chemother 51: 1889-1896.
38. Iwai A, Marusawa H, Takada Y, Egawa H, Ikeda K, et al. (2006) Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection. J Viral Hepat 13: 523-531.
39. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, et al. (2007) Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 13: 470-476.
40. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, et al. (2000) Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31: 488-495.
41. Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G, (2010) Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics 11: 137.
42. Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, et al. (1996) Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272: 537-542.